<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group>
<journal-title>PLoS Pathogens</journal-title></journal-title-group>
<issn pub-type="ppub">1553-7366</issn>
<issn pub-type="epub">1553-7374</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PPATHOGENS-D-13-03404</article-id>
<article-id pub-id-type="doi">10.1371/journal.ppat.1004154</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Pearls</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Oxidative damage</subject></subj-group></subj-group><subj-group><subject>Cell biology</subject><subj-group><subject>Signal transduction</subject></subj-group></subj-group><subj-group><subject>Computational biology</subject><subj-group><subject>Population modeling</subject><subj-group><subject>Infectious disease modeling</subject></subj-group></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Clinical immunology</subject><subj-group><subject>HIV immunopathogenesis</subject></subj-group></subj-group><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group><subj-group><subject>Immune evasion</subject><subject>Immunity</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antivirals</subject></subj-group></subj-group></subj-group><subj-group><subject>Virology</subject><subj-group><subject>Viral immune evasion</subject><subject>Viral persistence and latency</subject><subject>Viral replication</subject><subject>Viruses and cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>HIV clinical manifestations</subject></subj-group></subj-group><subj-group><subject>Infectious diseases</subject><subj-group><subject>Infectious disease control</subject><subject>Viral diseases</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Basic cancer research</subject><subj-group><subject>Tumor physiology</subject><subject>Viral and bacterial causes of cancer</subject></subj-group></subj-group><subj-group><subject>Cancer risk factors</subject><subj-group><subject>Environmental causes of cancer</subject></subj-group></subj-group><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>AIDS-related cancers</subject></subj-group></subj-group><subj-group><subject>Cancer treatment</subject><subj-group><subject>Antiangiogenesis therapy</subject></subj-group></subj-group><subj-group><subject>Cancer prevention</subject></subj-group></subj-group><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogenesis</subject><subj-group><subject>Host-pathogen interactions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Research and analysis methods</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Animal models</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Molecular and Cellular Mechanisms of KSHV Oncogenesis of Kaposi's Sarcoma Associated with HIV/AIDS</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cavallin</surname><given-names>Lucas E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Goldschmidt-Clermont</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mesri</surname><given-names>Enrique A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>AIDS Malignancies Scientific Working Group, Miami Center for AIDS Research, Department and Graduate Program of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, United States of America</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Viral Oncology Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Condit</surname><given-names>Richard C.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Florida, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">emesri@med.miami.edu</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>7</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>10</day><month>7</month><year>2014</year></pub-date>
<volume>10</volume>
<issue>7</issue>
<elocation-id>e1004154</elocation-id><permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Cavallin et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><funding-group><funding-statement>This work was supported by NIH grants CA136387 to EAM and PGC, by NCI/OHAM supplements from the Miami CFAR grant and by CFAR grant 5P30AI073961 to EAM, and by a Florida Biomedical Foundation BankHead Coley Grant 3BB05 to EAM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="4"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>AIDS-Associated Kaposi's Sarcoma: An Oncogenic Consequence of Infection with KSHV and HIV</title>
<p>Twenty years after its discovery <xref ref-type="bibr" rid="ppat.1004154-Chang1">[1]</xref>, Kaposi's sarcoma herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) continues to be an enigmatic oncovirus, while AIDS-associated Kaposi's sarcoma (AIDS-KS) remains a clinical challenge in endemic regions in Africa and for some patients receiving anti-retroviral therapy (ART) <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>–<xref ref-type="bibr" rid="ppat.1004154-Casper1">[4]</xref>. KSHV, a gamma-2 herpesvirus, is the etiological agent of Kaposi's sarcoma (KS) <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>: (1) KSHV is strictly associated with all clinical forms of the disease, including classic KS affecting elderly individuals of Mediterranean or Ashkenazi origin, transplant-associated KS, endemic KS affecting sub-Saharan countries, and AIDS-associated or epidemic KS. (2) KSHV is found in KS spindle cells. (3) KSHV infection precedes the onset of KS. (4) KSHV seroprevalence is higher in areas of high KS incidence. (5) KSHV encodes many viral oncogenes. (6) KSHV transforms and induces tumorigenesis in endothelial cell lineage <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>, <xref ref-type="bibr" rid="ppat.1004154-An1">[5]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Ashlock1">[6]</xref>. Like other human oncogenic viruses <xref ref-type="bibr" rid="ppat.1004154-Mesri2">[7]</xref>, KSHV infection alone is generally not sufficient to cause KSHV-associated cancers, which also include two B-cell lymphoproliferative disorders associated with HIV/AIDS: Multicentric Castlemans Disease and Primary Effussion Lymphoma <xref ref-type="bibr" rid="ppat.1004154-Cesarman1">[8]</xref>. This indicates that other co-factors are necessary for malignant transformation <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri2">[7]</xref>. KSHV seroprevalence in the general population ranges from less than 10% in the United States and Northern Europe to 30%–50% in endemic areas, where KS lifetime-incidence could be as high as 1% <xref ref-type="bibr" rid="ppat.1004154-Martin1">[9]</xref>. KS incidence increases dramatically in HIV-infected individuals, indicating that HIV/AIDS is a potent co-factor for KSHV oncogenesis <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>–<xref ref-type="bibr" rid="ppat.1004154-Casper1">[4]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Martin1">[9]</xref>. Yet, even in this high-risk group, the majority of KSHV-infected individuals will not develop KS, indicating that complex interactions between KSHV, genetic susceptibility, immune status, and HIV infection determine the oncogenic outcome of KSHV infection.</p>
</sec><sec id="s2">
<title>The Cellular Origin of KS: In Search of the Mysterious KS Spindle Cell Progenitor</title>
<p>AIDS-KS lesions are characterized by proliferating KSHV-infected spindle cells, intense angiogenesis with erythrocyte extravasation, and inflammatory cell infiltration <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>. The origin of the spindle cells remains enigmatic, because they express markers of multiple cellular lineages, including endothelial, monocytic, and smooth muscle <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>. Although KSHV infection results in important morphological and transcriptional changes that convey traits of cell transformation, few of these cell types can become transformed and tumorigenic <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>. The heterogeneous expression of cellular markers and the multifocal nature of KS lesions suggests that a circulating hematopoietic progenitor cell (HSC) could give rise to KS spindle cells, especially endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSC), as they both have the capacity to differentiate into endothelial lineage <xref ref-type="bibr" rid="ppat.1004154-Cancian1">[10]</xref>. Evidence pointing to the existence of a circulating KS progenitor, which is increased in AIDS-KS <xref ref-type="bibr" rid="ppat.1004154-Browning1">[11]</xref>, includes: (a) KS spindle cells in renal-transplant recipients are from donor origin <xref ref-type="bibr" rid="ppat.1004154-Barozzi1">[12]</xref>. (b) KS exhibits the “Koebner phenomenon,” whereby KS lesions appear at sites of injuries, suggesting that inflammatory cytokines can recruit circulating KS progenitors to the site of trauma <xref ref-type="bibr" rid="ppat.1004154-Cancian1">[10]</xref>. (c) Inflammatory cytokines, elevated in HIV/AIDS, can recruit potential KS progenitors and induce spindle cell differentiation and proliferation <xref ref-type="bibr" rid="ppat.1004154-Browning1">[11]</xref>. (d) Three KS models made from mouse endothelial lineage HSC cells <xref ref-type="bibr" rid="ppat.1004154-Ashlock1">[6]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mutlu1">[13]</xref> and one from rat MSC <xref ref-type="bibr" rid="ppat.1004154-Jones1">[14]</xref> formed tumors in a KSHV-dependent manner, suggesting that these populations contain cell types in which KSHV infection is oncogenic.</p>
<p>Identifying the KS progenitor is complex since KSHV infection causes transcriptional reprogramming and KSHV can infect many cell types due to broad expression of its entry receptors, the α3β5 integrin (ITGA3/ITGB5) and the EphrinA-receptor-2 (EPHA2). Thus, it is difficult to know whether the phenotypic markers of infected KS spindle cells correspond to those of the target cells, or are the consequence of KSHV's ability to reprogram host-cell transcription <xref ref-type="bibr" rid="ppat.1004154-Ashlock1">[6]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Cancian1">[10]</xref>.</p>
</sec><sec id="s3">
<title>KSHV Encodes an Oncogenic Armamentarium with the Potential to Induce All Malignant Phenotypic Characteristics of KS</title>
<p>KSHV encodes for several viral oncogenes, including 14 host homologues that carry the potential to induce all the malignant phenotypic characteristics—cancer hallmarks—of KS <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri2">[7]</xref>. KSHV can establish either a latent or lytic infection. Latency is an immune-silent state in which KSHV replicates along with the host by expressing a restricted number of genes needed for episomal maintenance <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>. During lytic infection, KSHV expresses the full replication program to produce new virions. Latent gene expression favors viral persistence and replication by promoting host-cell proliferation and survival (reviewed in <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>). Among the latent KSHV genes, LANA was shown to inactivate the p53 and pRB tumor suppressor pathways <xref ref-type="bibr" rid="ppat.1004154-Radkov1">[15]</xref>. The KSHV cyclin homologue (v-cyclin) is able to induce cell cycle entry by counteracting both p21 and p27 Cyclin-dependent kinase (CDK) inhibitors <xref ref-type="bibr" rid="ppat.1004154-Swanton1">[16]</xref>. The viral FLICE-inhibitory protein (vFLIP) can constitutively activate NFkB, promoting cell survival by up-regulating transcription of anti-apoptotic genes such as <italic>BCL-2</italic> and <italic>A20</italic> <xref ref-type="bibr" rid="ppat.1004154-Guasparri1">[17]</xref>. Other KSHV latent genes, such as Kaposin (K12) and the KSHV-encoded miRNA <xref ref-type="bibr" rid="ppat.1004154-Zhu1">[18]</xref>, have been shown to further collaborate in inducing the KS malignant phenotype.</p>
<p>KSHV lytic expression includes genes that favor viral replication by affecting the DNA damage response, promoting survival, and evading the immune response. As a consequence, lytic genes can induce the following KS malignant phenotypes: (1) Immune evasion <xref ref-type="bibr" rid="ppat.1004154-Coscoy1">[19]</xref>: IRF homologues (vIRFs 1–4) can inhibit the IFN response and ORFK4 inhibits the complement system, while K3 and K5 down-regulate immune recognition genes by ubiquitination. (2) Genetic instability: vIRF-1 can obstruct the DNA damage response by inhibiting p53-mediated activation of ATM, and the viral G protein-coupled receptor (vGPCR) can induce oxidative DNA damage via Rac1-mediated activation of ROS <xref ref-type="bibr" rid="ppat.1004154-Ma1">[20]</xref>. (3) Anti-apoptosis: vGPCR and K1 have been shown to activate the anti-apoptotic NFkB pathway while vIRF-1 was shown to inhibit BH3-only proapoptotic mediators, such as BIM.</p>
<p>KSHV lytic genes may also favor reinfection of KS progenitors by inducing angiogenesis and inflammation that help to recruit un-infected endothelial-lineage and hematopoietic cells. vGPCR, a constitutively active homolog of the Groα and IL-8 receptors CXCR1/2, activates MAPKs, NFkB, and PI3K-AKT-mTOR pathways, leading to an angiogenic switch and endothelial cell immortalization caused by up-regulation of VEGF and its receptor-2 KDR (VEGFR2) <xref ref-type="bibr" rid="ppat.1004154-Bais1">[21]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Bais2">[22]</xref>. vGPCR induces angiogenic KS-like tumors in transgenic mice by up-regulating VEGF, IL-6, Angiopoietin-2 (ANGPT2), and PDGF <xref ref-type="bibr" rid="ppat.1004154-Jensen1">[23]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Sodhi1">[24]</xref>. K1 contains an ITAM motif that is able to constitutively induce angiogenic and inflammatory responses via AKT and NFkB <xref ref-type="bibr" rid="ppat.1004154-Wang1">[25]</xref>. In addition, KSHV encodes several virokines, including a viral IL-6 (vIL-6) that can potently activate gp130 signaling <xref ref-type="bibr" rid="ppat.1004154-Chen1">[26]</xref> and other viral homologs to angiogenic chemokines (vMIP-I/III or vCCL-I-III).</p>
</sec><sec id="s4">
<title>KSHV and Oncogenesis of AIDS-KS: A Puzzle at the Crossroads of KSHV Biology, Cellular Cancer Pathways, and HIV/AIDS</title>
<p>The remarkable oncogenic potential of KSHV conflicts with the fact that KSHV infection culminates in KS in certain epidemiological settings such as HIV infection and AIDS <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>. A paradox in KSHV oncogenesis appears to be the fact that KSHV canonical latent infection cannot transform cells. In contrast, lytic infection, which expresses KSHV angiogenic genes, is cytopathic and immunogenic and, therefore, cannot transform cells in immunocompetent individuals (<xref ref-type="fig" rid="ppat-1004154-g001">Figure 1</xref>) <xref ref-type="bibr" rid="ppat.1004154-Ganem1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>. Two hypotheses have been proposed: The “paracrine oncogenesis” hypothesis (<xref ref-type="fig" rid="ppat-1004154-g001">Figures 1B</xref> and <xref ref-type="fig" rid="ppat-1004154-g002">2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref> is based on the presence of lytically infected cells or latently infected cells expressing early lytic genes <xref ref-type="bibr" rid="ppat.1004154-Chang2">[27]</xref> in KS lesions. These cells express angiogenic genes, such as vGPCR, K1, and ORF45, that promote the production of angiogenic and KS growth factors (VEGF, IL-6, PDGF), which together with the virokines, stimulate the proliferation of latently infected cells and angiogenesis in a paracrine manner (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Montaner1">[28]</xref>. Another compatible scenario is the “abortive lytic” hypothesis (<xref ref-type="fig" rid="ppat-1004154-g001">Figure 1</xref>) <xref ref-type="bibr" rid="ppat.1004154-Bais2">[22]</xref>, in which cells expressing the oncogenic early lytic genes—but not the full lytic program <xref ref-type="bibr" rid="ppat.1004154-Chang2">[27]</xref>—can be transformed by genetic or epigenetic oncogenic alterations and switch back to less immunogenic latent forms, which will be paracrinally stimulated by lytically infected cells <xref ref-type="bibr" rid="ppat.1004154-Bais2">[22]</xref>. These hypotheses are supported by laboratory findings that show the paracrine nature of vGPCR-induced tumors <xref ref-type="bibr" rid="ppat.1004154-Jensen1">[23]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Sodhi1">[24]</xref> and their ability to support the tumorigenicity of latent KSHV genes via paracrine mechanisms <xref ref-type="bibr" rid="ppat.1004154-Montaner1">[28]</xref>. These models can explain the high incidence of KS in HIV/AIDS. Angiogenic HIV-Tat and elevated inflammatory cytokines in AIDS patients that result from chronic immune activation can induce KSHV lytic reactivation and promote KS development <xref ref-type="bibr" rid="ppat.1004154-Aoki1">[29]</xref>. Furthermore, cells expressing the more immunogenic lytic genes necessary to initiate or to support KS tumors would not be eliminated in the context of AIDS immunosuppression (<xref ref-type="fig" rid="ppat-1004154-g001">Figure 1</xref>) <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Bihl1">[30]</xref>.</p>
<fig id="ppat-1004154-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1004154.g001</object-id><label>Figure 1</label><caption>
<title>KSHV pathobiology in healthy and HIV/AIDS patients.</title>
<p>(A) In a healthy host, KSHV infection of a KS progenitor is not oncogenic, since it leads to latent infection or to cytopathic lytic replication. Reactivation leading to oncogenic lytic gene expression is under immunological control. (B) Scenario for AIDS-KS pathogenesis according to the Paracrine Oncogenesis and Abortive Lytic Hypotheses. In HIV/AIDS, decreased immunosurveilance, inflammatory cytokines and HIV Tat lead to KSHV reactivation and reinfection. This leads to increased, uncontrolled, early lytic oncogenic gene expression, with concomitant risk of cell transformation by somatic host cell oncogenic alterations. Upon transformation, cells shut down early lytic oncogenes. Latently infected transformed cells are stimulated in a paracrine manner by angiogenic and proliferative factors released from lytically infected or abortive lytic cells (paracrine oncogenesis, see details in <xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>). In addition, lytically infected cells provide a constant source of virions for reinfection, while angiogenesis and inflammation recruit target KS progenitors. ART inhibits KSHV reactivation and lytic replication through immune reconstitution and decreased levels of HIV viral loads. Gancyclovir inhibits viral replication and lytic gene expression.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1004154.g001" position="float" xlink:type="simple"/></fig><fig id="ppat-1004154-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1004154.g002</object-id><label>Figure 2</label><caption>
<title>Molecular mechanisms, therapeutic targets, and clinically tested drugs in AIDS-KS paracrine viral oncogenesis.</title>
<p>In KS spindle cells lytically infected with KSHV cells or latently infected spindle cells expressing early lytic genes, KSHV genes such vGPCR, K1, and ORF45 constitutively trigger signaling cascades, leading to mTOR and ROS activation, which induce transcription and translation of PDGF and VEGF. These secreted growth factors can act in a paracrine manner to activate the same signaling cascades in latently infected cells expressing VEGF and PDGF receptors to drive KS cell proliferation and angiogenesis. Rapamycin (RAPA), which inhibits mTOR, and Imatinib (IMA), which inhibits PDGFR, can interrupt this paracrine loop to target KSHV tumorigenesis. Both drugs have shown efficacy in AIDS-KS clinical trials.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1004154.g002" position="float" xlink:type="simple"/></fig></sec><sec id="s5">
<title>Identification and Validation of Cellular Targets Implicated in KSHV-Induced Paracrine Oncogenesis</title>
<p>Growth factor signaling pathways mediating KSHV-paracrine oncogenesis are attractive therapeutic targets in AIDS-KS (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>). They can be targeted by FDA-approved drugs and preclinically tested in available mouse models of KSHV-induced KS <xref ref-type="bibr" rid="ppat.1004154-Mesri1">[3]</xref>, <xref ref-type="bibr" rid="ppat.1004154-An1">[5]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Ashlock1">[6]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Mutlu1">[13]</xref>. vGPCR is essential for KSHV tumorigenesis and angiogenesis <xref ref-type="bibr" rid="ppat.1004154-Mutlu1">[13]</xref>. vGPCR has been shown to induce KS-like tumors via the PI3K-AKT-mTOR axis by regulating expression of angiogenic growth factors as well as their paracrine activities (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Sodhi1">[24]</xref>. Accordingly, vGPCR tumorigenesis is blocked by the mTORC1 inhibitor rapamycin and by PI3Kγ inhibitors <xref ref-type="bibr" rid="ppat.1004154-Sodhi1">[24]</xref>. Furthermore, the growth of KSHV-infected xenografts was blocked by rapamycin and other rapalogs through inhibition of VEGF-angiogenesis (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Roy1">[31]</xref>. Another druggable pathway is production of reactive oxygen species (ROS) by activation of NADPH oxidase via RAC1, a downstream mediator of vGPCR-angiogenesis overexpressed in AIDS-KS lesions <xref ref-type="bibr" rid="ppat.1004154-Ma1">[20]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Ma2">[32]</xref>. The ROS scavenger N-Acetyl-Cysteine (NAC) was shown to inhibit KS-like tumorigenesis in a RAC1 as well as a KSHV-induced KS mouse model <xref ref-type="bibr" rid="ppat.1004154-Ma1">[20]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Ma2">[32]</xref>. ROS appear to play a role in paracrine oncogenesis through PDGF-mediated stimulation of cell proliferation and tumor angiogenesis mediated by STAT3 transcription of VEGF and MYC (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Ma1">[20]</xref>. Notch signaling is another important pathway activated by KSHV infection via vFLIP, vGPCR, or by regulating miR30 to promote the KS-malignant phenotype and induce angiogenesis <xref ref-type="bibr" rid="ppat.1004154-Zhu1">[18]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Liu1">[33]</xref>. Targeting the Notch pathway with a gamma-secretase inhibitor and soluble Dll4 inhibited growth of KSHV-transformed endothelial cells in vitro and in vivo <xref ref-type="bibr" rid="ppat.1004154-Liu1">[33]</xref>. Another mediator of KSHV angiogenesis is the VEGFR2-glycan binding lectin galectin-1 <xref ref-type="bibr" rid="ppat.1004154-Croci1">[34]</xref>, which is up-regulated by ROS–dependent activation of NFκB and can elicit VEGF-like signaling. A therapeutic anti-gal-1 mAb promoted KS-spindle cell xenograft regression <xref ref-type="bibr" rid="ppat.1004154-Croci1">[34]</xref>.</p>
</sec><sec id="s6">
<title>Translational AIDS-KS Medicine and Development of Rationally Designed Therapies</title>
<p>Progress in prevention and treatment of AIDS-KS is the consequence of advances in controlling HIV/AIDS as well as KSHV oncogenesis <xref ref-type="bibr" rid="ppat.1004154-Dittmer1">[35]</xref>. Implementation of ART led to a 6-fold decrease in AIDS-KS incidence and the regression of established AIDS-KS lesions <xref ref-type="bibr" rid="ppat.1004154-Dittmer1">[35]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Nguyen1">[36]</xref>, while inhibition of KSHV-replication with gancyclovir decreased KS incidence in AIDS patients <xref ref-type="bibr" rid="ppat.1004154-Martin2">[37]</xref>. This is consistent with: (1) an oncogenic role of KSHV lytic replication, which is also more immunogenic and, thus, suppressed by ART-mediated immune reconstitution <xref ref-type="bibr" rid="ppat.1004154-Bihl1">[30]</xref>; (2) the tumor-promoting role of HIV infection, which is targeted by ART (<xref ref-type="fig" rid="ppat-1004154-g001">Figure 1B</xref>); and (3) protease inhibitors present in some ART regimens with anti-tumor, anti-angiogenic, or anti-KSHV activities <xref ref-type="bibr" rid="ppat.1004154-Monini1">[38]</xref>. AIDS-KS can present clinically as a limited, localized disease that responds to local therapies (surgical excision, cryosurgery, radiotherapy, and intralesional vinblastine) <xref ref-type="bibr" rid="ppat.1004154-Dittmer1">[35]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Nguyen1">[36]</xref>. AIDS-KS can also present as an aggressive, rapidly progressing, disseminated cutaneous lesion generally associated with visceral involvement that requires systemic cytotoxic chemotherapy in addition to ART <xref ref-type="bibr" rid="ppat.1004154-Dittmer1">[35]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Nguyen1">[36]</xref>. Although Food and Drug Administration (FDA)-approved liposomal anthracyclines (doxorubicin and daunorubicin) are effective as first-line treatment for disseminated AIDS-KS, it is estimated that more than half of these patients will not be cured <xref ref-type="bibr" rid="ppat.1004154-Nguyen1">[36]</xref>; therefore, new and less toxic treatment modalities are needed.</p>
<p>Advances in the molecular understanding of KS oncogenesis have provided a basis for the development of several targeted interventions (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Dittmer1">[35]</xref>. Rapamycin inhibits mTORC1, a druggable target activated by vGPCR, K1, and ORF45 <xref ref-type="bibr" rid="ppat.1004154-Sodhi1">[24]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Wang1">[25]</xref>, <xref ref-type="bibr" rid="ppat.1004154-Chang2">[27]</xref>, which is essential for protein translation and cell proliferation. Rapamycin was reported to cause regression of transplant-related KS <xref ref-type="bibr" rid="ppat.1004154-Stallone1">[39]</xref>, and its use in experimental KSHV-infected xenograft models proved to have antitumorigenic effects <xref ref-type="bibr" rid="ppat.1004154-Roy1">[31]</xref>. A recent pilot study in AIDS-KS patients showed that Rapamycin administration, in combination with ART, induced partial and total responses in some patients <xref ref-type="bibr" rid="ppat.1004154-Krown1">[40]</xref>. These responses correlated with down-regulation of mTORC1 downstream targets. Other important studies in AIDS-KS patients used Imatinib/Gleevec, which targets paracrine and autocrine tumor and angiogenic activities mediated by c-Kit and PDGFRβ (<xref ref-type="fig" rid="ppat-1004154-g002">Figure 2</xref>) <xref ref-type="bibr" rid="ppat.1004154-Koon1">[41]</xref>. In this study, 50% of patients experienced a partial response that correlated with decreased phosphorylation of PDGFRβ <xref ref-type="bibr" rid="ppat.1004154-Koon1">[41]</xref>. A more recent Imatinib Phase clinical II trial showed an overall response of 33%, validating c-Kit and PDGFR as promising KS targets <xref ref-type="bibr" rid="ppat.1004154-Koon2">[42]</xref>. Other anti-angiogenic phase II trials showing clinical responses include bevacizumab/Avastin, a humanized anti-VEGF-A monoclonal antibody. These studies show that targeting paracrine mechanisms of KSHV oncogenesis is a viable approach to treat AIDS-KS patients. The continuous success of these pathogenesis-based therapies relies on understanding the close interplay between KSHV biology and the host malignant phenotype, which should inform clinical-study design and interpretation.</p>
</sec></body>
<back>
<ack>
<p>We would like to thank all our colleagues for their important contributions to this field of research. We deeply regret not being able to comprehensively reference their work because of space limitations. The authors would like to thank all members of the Mesri Lab, in particular, Brittany Ashlock for her contributions and discussions regarding KS progenitors and new animal models. We would like to thank Santas Rosario for thoughtful editing and proofreading.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="ppat.1004154-Chang1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pessin</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Culpepper</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>1994</year>) <article-title>Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma</article-title>. <source>Science</source> <volume>266</volume>: <fpage>1865</fpage>–<lpage>1869</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Ganem1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganem</surname><given-names>D</given-names></name> (<year>2010</year>) <article-title>KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine</article-title>. <source>J Clin Invest</source> <volume>120</volume>: <fpage>939</fpage>–<lpage>949</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Mesri1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mesri</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Boshoff</surname><given-names>C</given-names></name> (<year>2010</year>) <article-title>Kaposi's sarcoma and its associated herpesvirus</article-title>. <source>Nat Rev Cancer</source> <volume>10</volume>: <fpage>707</fpage>–<lpage>719</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Casper1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Casper</surname><given-names>C</given-names></name> (<year>2011</year>) <article-title>The increasing burden of HIV-associated malignancies in resource-limited regions</article-title>. <source>Annu Rev Med</source> <volume>62</volume>: <fpage>157</fpage>–<lpage>170</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-An1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>An</surname><given-names>FQ</given-names></name>, <name name-style="western"><surname>Folarin</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Compitello</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gerson</surname><given-names>SL</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo</article-title>. <source>J Virol</source> <volume>80</volume>: <fpage>4833</fpage>–<lpage>4846</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Ashlock1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashlock</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Isaac</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mesri</surname><given-names>EA</given-names></name> (<year>2014</year>) <article-title>Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication</article-title>. <source>PLoS ONE</source> In press.</mixed-citation>
</ref>
<ref id="ppat.1004154-Mesri2"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mesri</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Feitelson</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Munger</surname><given-names>K</given-names></name> (<year>2014</year>) <article-title>Human Viral Oncogenesis: A Cancer Hallmarks Analysis</article-title>. <source>Cell Host Microbe</source> <volume>15</volume>: <fpage>266</fpage>–<lpage>282</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Cesarman1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name> (<year>2014</year>) <article-title>Gammaherpesviruses and lymphoproliferative disorders</article-title>. <source>Annu Rev Pathol</source> <volume>9</volume>: <fpage>349</fpage>–<lpage>372</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Martin1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martin</surname><given-names>JN</given-names></name> (<year>2011</year>) <article-title>Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and Kaposi sarcoma</article-title>. <source>Adv Dent Res</source> <volume>23</volume>: <fpage>76</fpage>–<lpage>78</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Cancian1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cancian</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boshoff</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming</article-title>. <source>Trends Cell Biol</source> <volume>23</volume>: <fpage>421</fpage>–<lpage>432</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Browning1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Browning</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Sechler</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Washington</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>1994</year>) <article-title>Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls</article-title>. <source>Blood</source> <volume>84</volume>: <fpage>2711</fpage>–<lpage>2720</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Barozzi1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barozzi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Luppi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Facchetti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mecucci</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Alu</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors</article-title>. <source>Nat Med</source> <volume>9</volume>: <fpage>554</fpage>–<lpage>561</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Mutlu1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mutlu</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Cavallin</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Vincent</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chiozzini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Eroles</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma</article-title>. <source>Cancer Cell</source> <volume>11</volume>: <fpage>245</fpage>–<lpage>258</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Jones1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jones</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bedolla</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV</article-title>. <source>J Clin Invest</source> <volume>122</volume>: <fpage>1076</fpage>–<lpage>1081</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Radkov1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Radkov</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Kellam</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Boshoff</surname><given-names>C</given-names></name> (<year>2000</year>) <article-title>The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells</article-title>. <source>Nat Med</source> <volume>6</volume>: <fpage>1121</fpage>–<lpage>1127</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Swanton1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Swanton</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mann</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Fleckenstein</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Neipel</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins</article-title>. <source>Nature</source> <volume>390</volume>: <fpage>184</fpage>–<lpage>187</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Guasparri1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guasparri</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name> (<year>2004</year>) <article-title>KSHV vFLIP is essential for the survival of infected lymphoma cells</article-title>. <source>J Exp Med</source> <volume>199</volume>: <fpage>993</fpage>–<lpage>1003</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Zhu1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Haecker</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Renne</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>gamma-Herpesvirus-encoded miRNAs and their roles in viral biology and pathogenesis</article-title>. <source>Curr Opin Virol</source> <volume>3</volume>: <fpage>266</fpage>–<lpage>275</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Coscoy1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coscoy</surname><given-names>L</given-names></name> (<year>2007</year>) <article-title>Immune evasion by Kaposi's sarcoma-associated herpesvirus</article-title>. <source>Nat Rev Immunol</source> <volume>7</volume>: <fpage>391</fpage>–<lpage>401</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Ma1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Cavallin</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Chiozzini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Goldschmidt-Clermont</surname><given-names>PJ</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis</article-title>. <source>Antioxid Redox Signal</source> <volume>18</volume>: <fpage>80</fpage>–<lpage>90</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Bais1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bais</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Santomasso</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Coso</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Arvanitakis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Raaka</surname><given-names>EG</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator</article-title>. <source>Nature</source> <volume>391</volume>: <fpage>86</fpage>–<lpage>89</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Bais2"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bais</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Van Geelen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eroles</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mutlu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chiozzini</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR</article-title>. <source>Cancer Cell</source> <volume>3</volume>: <fpage>131</fpage>–<lpage>143</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Jensen1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jensen</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Manfra</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Grisotto</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Vassileva</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma</article-title>. <source>J Immunol</source> <volume>174</volume>: <fpage>3686</fpage>–<lpage>3694</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Sodhi1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sodhi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chaisuparat</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ramsdell</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Manning</surname><given-names>BD</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor</article-title>. <source>Cancer Cell</source> <volume>10</volume>: <fpage>133</fpage>–<lpage>143</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Wang1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dittmer</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Tomlinson</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Fakhari</surname><given-names>FD</given-names></name>, <name name-style="western"><surname>Damania</surname><given-names>B</given-names></name> (<year>2006</year>) <article-title>Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus</article-title>. <source>Cancer Res</source> <volume>66</volume>: <fpage>3658</fpage>–<lpage>3666</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Chen1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sandford</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nicholas</surname><given-names>J</given-names></name> (<year>2009</year>) <article-title>Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6</article-title>. <source>J Virol</source> <volume>83</volume>: <fpage>722</fpage>–<lpage>733</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Chang2"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chang</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Ganem</surname><given-names>D</given-names></name> (<year>2013</year>) <article-title>A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity</article-title>. <source>Cell Host Microbe</source> <volume>13</volume>: <fpage>429</fpage>–<lpage>440</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Montaner1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Montaner</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sodhi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ramsdell</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma</article-title>. <source>Cancer Res</source> <volume>66</volume>: <fpage>168</fpage>–<lpage>174</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Aoki1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aoki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tosato</surname><given-names>G</given-names></name> (<year>2007</year>) <article-title>Interactions between HIV-1 Tat and KSHV</article-title>. <source>Curr Top Microbiol Immunol</source> <volume>312</volume>: <fpage>309</fpage>–<lpage>326</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Bihl1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bihl</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mosam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>LN</given-names></name>, <name name-style="western"><surname>Chisholm</surname><given-names>JV</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Dollard</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma</article-title>. <source>AIDS</source> <volume>21</volume>: <fpage>1245</fpage>–<lpage>1252</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Roy1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roy</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sin</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Lucas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Venkataramanan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis</article-title>. <source>Cancer Res</source> <volume>73</volume>: <fpage>2235</fpage>–<lpage>2246</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Ma2"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Cavallin</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Duran</surname><given-names>EM</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>106</volume>: <fpage>8683</fpage>–<lpage>8688</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Liu1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Tulpule</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Scehnet</surname><given-names>JS</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>KSHV-induced notch components render endothelial and mural cell characteristics and cell survival</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>887</fpage>–<lpage>895</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Croci1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Croci</surname><given-names>DO</given-names></name>, <name name-style="western"><surname>Salatino</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rubinstein</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cerliani</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Cavallin</surname><given-names>LE</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma</article-title>. <source>J Exp Med</source> <volume>209</volume>: <fpage>1985</fpage>–<lpage>2000</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Dittmer1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dittmer</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Krown</surname><given-names>SE</given-names></name> (<year>2007</year>) <article-title>Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus</article-title>. <source>Curr Opin Oncol</source> <volume>19</volume>: <fpage>452</fpage>–<lpage>457</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Nguyen1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nguyen</surname><given-names>HQ</given-names></name>, <name name-style="western"><surname>Magaret</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Kitahata</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Van Rompaey</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Wald</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response</article-title>. <source>AIDS</source> <volume>22</volume>: <fpage>937</fpage>–<lpage>945</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Martin2"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martin</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Kuppermann</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Wolitz</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Palestine</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group</article-title>. <source>N Engl J Med</source> <volume>340</volume>: <fpage>1063</fpage>–<lpage>1070</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Monini1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Toschi</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name> (<year>2004</year>) <article-title>Antitumour effects of antiretroviral therapy</article-title>. <source>Nat Rev Cancer</source> <volume>4</volume>: <fpage>861</fpage>–<lpage>875</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Stallone1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stallone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schena</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Infante</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Di Paolo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Loverre</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Sirolimus for Kaposi's sarcoma in renal-transplant recipients</article-title>. <source>N Engl J Med</source> <volume>352</volume>: <fpage>1317</fpage>–<lpage>1323</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Krown1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Krown</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Dezube</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>EG</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study</article-title>. <source>J Acquir Immune Defic Syndr</source> <volume>59</volume>: <fpage>447</fpage>–<lpage>454</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Koon1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koon</surname><given-names>HB</given-names></name>, <name name-style="western"><surname>Bubley</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Pantanowitz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Masiello</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Imatinib-induced regression of AIDS-related Kaposi's sarcoma</article-title>. <source>J Clin Oncol</source> <volume>23</volume>: <fpage>982</fpage>–<lpage>989</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1004154-Koon2"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koon</surname><given-names>HB</given-names></name>, <name name-style="western"><surname>Krown</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rapisuwon</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042</article-title>. <source>J Clin Oncol</source> <volume>32</volume>: <fpage>402</fpage>–<lpage>408</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>